MMP7

Six Arizona Startups Driving Biosciences Forward in 2024

Retrieved on: 
Wednesday, April 3, 2024
Other Philanthropy, Other Science, Pharmaceutical, Oncology, Start-Up, Medical Devices, Infectious Diseases, Professional Services, Foundation, Genetics, Philanthropy, Science, Veterinary, Clinical Trials, FDA, General Health, Biotechnology, Surgery, Health, Entrepreneurship, AI, Quality of life, Surgeon, Dog, MMP7, Hepatology, Itch

Each startup will receive $30,000 in non-dilutive funding via the Arizona Bioindustry Association, the Flinn Foundation’s nonprofit partner.

Key Points: 
  • Each startup will receive $30,000 in non-dilutive funding via the Arizona Bioindustry Association, the Flinn Foundation’s nonprofit partner.
  • AZBio will also assist in developing a personalized learning plan and offer support services for the participants.
  • The product is a treatment for itching caused by canine atopic dermatitis with topical and oral administration.
  • This product will require a single blood draw, with results the same day, aiming to simplify and accelerate care while significantly reducing health care costs for children.

Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023

Retrieved on: 
Monday, September 11, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Arrowhead, European Respiratory Society, RAGE, Asthma, International, Serum, Gastric lavage, TSLP, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., RNA, Lung, ERS, MUC5AC, Arrowhead Pharmaceuticals, Patient, MMP7, BALF, RNA interference, International Congress on Tuberculosis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.
  • Reduction of serum sRAGE was similar in healthy volunteers and in patients with asthma at the 44 mg dose level.
  • Based on interim blinded safety results from the ongoing study, ARO-RAGE has been well-tolerated to date in healthy volunteers and asthma patients.
  • “Today we announced additional data on multiple programs from our emerging pipeline of first-in-class pulmonary targeted RNAi therapeutic candidates at the European Respiratory Society International Congress.

Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results

Retrieved on: 
Monday, February 6, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Molecule, Moyamoya disease, Trial of the century, NEJM, AHA, SEQUOIA, FCS, PIN, Safety, High-density lipoprotein, Outline, American Heart Association, Patient, Webcast, APOC3, MMP7, Sale, The New England Journal of Medicine, Therapy, Gout, IPF, Takeda, Liver disease, Triglyceride, RNA interference, Idiopathic pulmonary fibrosis, Horizon Therapeutics, Cardiovascular disease, Pharmacokinetics, Hypertriglyceridemia, Arrowhead, Cryptocurrency, Pharmaceutical industry, Amgen

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022.
  • The company is hosting a conference call today, February 6, 2023, at 4:30 p.m.
  • ET to discuss the results.
  • Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Thursday, February 2, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, MBA, Arrowhead Pharmaceuticals, Safety, Patient, RNA, Inflammation, MMP7, Fibrosis, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., IPF, RNA interference, Idiopathic pulmonary fibrosis, Pharmacokinetics, Arrowhead, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).
  • “MMP7 is thought to play multiple roles in IPF pathogenesis, including promoting inflammation and aberrant epithelial repair and fibrosis,” said James Hamilton, M.D., MBA, chief of discovery and translational medicine at Arrowhead.
  • “ARO-MMP7 offers a novel approach to potentially address the significant unmet medical need that exists for patients with IPF, who experience progressive decline of lung function, despite currently available therapies.”
    AROMMP7-1001 ( NCT05537025 ) is a Phase 1/2a single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7 in up to 56 healthy volunteers and up to 21 patients with IPF.

Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results

Retrieved on: 
Monday, November 28, 2022
Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Other Science, Molecule, Arrowhead, American Heart Association, AHA, APOC3, MMP7, PIN, The New England Journal of Medicine, Triglyceride, RNA interference, NEJM, Hypertriglyceridemia, Patient, Cardiovascular disease, Moyamoya disease, Lipoprotein(a), Webcast, FCS, Sale, IPF, Royalty Pharma, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Amgen

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022.
  • The company is hosting a conference call today, November 28, 2022, at 4:30 p.m.
  • ET to discuss the results.
  • Presented interim data on the cardiometabolic pipeline in three late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2022 and at a virtual analyst and investor event.

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, August 17, 2022
Pharmaceutical, Health, Clinical Trials, U.S. Securities and Exchange Commission, MMP7, Gene silencing, RNA interference, Gene, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., IPF, Arrowhead Pharmaceuticals, Private Securities Litigation Reform Act, Clinical trial, Ethics committee, Annual report, Security (finance), Patient, Review, COVID-19, Company, Twitter, Therapy, Arrowhead, RNA, Mission statement, Safety, NASDAQ, Committee, News, MBA, Idiopathic pulmonary fibrosis, Degenerative disease, Time, Pharmacokinetics, Pharmaceutical industry

ARO-MMP7 is a further expansion of our robust clinical pipeline, which also includes additional lung disease product candidates, ARO-RAGE and ARO-MUC5AC.

Key Points: 
  • ARO-MMP7 is a further expansion of our robust clinical pipeline, which also includes additional lung disease product candidates, ARO-RAGE and ARO-MUC5AC.
  • Pending clearance, Arrowhead intends to proceed with AROMMP7-1001, a Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7 in up to 56 healthy volunteers and in up to 21 patients with IPF.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics

Retrieved on: 
Thursday, May 26, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Molecule, Inflammation, Risk, Mission statement, RNA transfection, International Congress on Tuberculosis, Company, European Respiratory Society, R, MUC5AC, Private Securities Litigation Reform Act, Toxicology, Gene, U.S. Securities and Exchange Commission, Arrowhead Pharmaceuticals, University of Kansas Medical Center, News, Patient, Asthma, NASDAQ, RNA interference, GLP, MPH, COVID-19, Investor, MMP7, Mouse, RATS, Literature, Primate, Fibrosis, RAGE, Folate targeting, Program, RNA, Safety, University, Gene silencing, Lung, Therapy, Pharmacodynamics, Sirna, Twitter, ERS, IPF, Pulmonary fibrosis, Overload, Security (finance), Annual report, Pharmaceutical industry, Arrowhead

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a pulmonary research & development (R&D) Day today in New York City to discuss its emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform.
  • A live and archived webcast of the event may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
  • The pulmonary targeted TRiMTM platform has come a long way since our first clinical candidate, ARO-ENaC.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.